• 1
    Weiss LM, Crogan EM, Muller-Hermelink HK, et al. Histiocytic sarcoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
  • 2
    Vos JA, Abbondanzo SL, Barekman CL, Andriko JW, Miettinen M, Aguilera NS. Histiocytic sarcoma: a study of 5 cases including the histiocyte marker CD163. Mod Pathol. 2005; 18: 693-704.
  • 3
    Hanson CA, Jaszcz W, Kersey JH, et al. True histiocytic lymphoma: histopathologic, immunophenotypic and genotypic analysis. Br J Haematol. 1989; 73: 187-198.
  • 4
    Lauritzen AF, Delsol G, Hansen NE, et al. Histiocytic sarcomas and monoblastic leukemias. A clinical, histologic, and immunophenotypical study. Am J Clin Pathol. 1994; 102: 45-54.
  • 5
    Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002; 41: 1-29.
  • 6
    Bouabdallah R, Abena P, Chetaille B, et al. True histiocytic lymphoma following B-acute lymphoblastic leukaemia: case report with evidence for a common clonal origin in both neoplasms. Br J Haematol. 2001; 113: 1047-1050.
  • 7
    Buonocore S, Valente AL, Nightingale D, Bogart J, Souid AK. Histiocytic sarcoma in a 3-year-old male: a case report. Pediatrics. 2005; 116: e322-e325.
  • 8
    Copie-Bergman C, Wotherspoon AC, Norton AJ, Diss TC, Isaacson PG. True histiocytic lymphoma: a morphologic, immunohistochemical, and molecular genetic study of 13 cases. Am J Surg Pathol. 1998; 22: 1386-1392.
  • 9
    Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004; 28: 1133-1144.
  • 10
    Kamel OW, Gocke CD, Kell DL, Cleary ML, Warnke RA. True histiocytic lymphoma: a study of 12 cases based on current definition. Leuk Lymphoma. 1995; 18: 81-86.
  • 11
    Murarescu ED, Lighezan R, Negru D, Chiselita IR, Plamadeala P, Mihailovici MS. Histiocytic sarcoma associated with Hodgkin's disease. Rom J Morphol Embryol. 2005; 46: 183-187.
  • 12
    Hale G, Swirsky DM, Hayhoe FG, Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med. 1983; 1: 321-334.
  • 13
    Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988; 2: 1394-1399.
  • 14
    Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998; 351: 1701-1702.
  • 15
    Gruessner RW, Kandaswamy R, Humar A, Gruessner AC, Sutherland DE. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation. 2005; 79: 1184-1189.
  • 16
    Tryphonopoulos P, Madariaga JR, Kato T, et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc. 2005; 37: 1203-1204.
  • 17
    Tzakis AG, Tryphonopoulos P, Kato T, et al. Intestinal transplantation: advances in immunosuppression and surgical techniques. Transplant Proc. 2003; 35: 1925-1926.
  • 18
    Ona ET, Danguilan RA, Africa J, et al. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation. Transplant Proc. 2008; 40: 2226-2229.
  • 19
    Bertz H, Spyridonidis A, Wasch R, Grullich C, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of de-escalation. Biol Blood Marrow Transplant. 2009; 15: 1563-1570.
  • 20
    Gupta V, Ball SE, Sage D, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant. 2005; 35: 467-471.
  • 21
    Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004; 104: 3865-3871.
  • 22
    Ahmed N, Leung KS, Rosenblatt H, et al. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008; 14: 1298-1304.
  • 23
    Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol. 2009; 144: 818-831.
  • 24
    Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma. 2001; 41: 77-87.
  • 25
    Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009; 27: 5425-5430.
  • 26
    Williams KM, Higman MA, Chen AR, et al. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer. 2008; 50: 667-670.
  • 27
    Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer. 2009; 53: 978-983.
  • 28
    Ambrose LR, Morel AS, Warrens AN. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood. 2009; 114: 3052-3055.
  • 29
    Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002; 100: 1715-1720.
  • 30
    Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003; 101: 1422-1429.
  • 31
    Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006; 12: 7174-7179.
  • 32
    Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005; 44: 251-254.
  • 33
    Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma. 2004; 45: 205-219.